Details for Patent: 8,309,569

Which drugs does patent 8,309,569 protect, and when does it expire?

Patent 8,309,569 protects XIFAXAN and is included in one NDA.

This patent has thirty patent family members in fifteen countries.

Summary for Patent: 8,309,569

Title:	Methods for treating diarrhea-associated irritable bowel syndrome
Abstract:	The present invention provides methods of treating diarrhea-associated irritable bowel syndrome (IBS-D) following rifaximin administration.
Inventor(s):	Forbes; William (Raleigh, NC), Johnson; Lorin (Palo Alto, CA)
Assignee:	Salix Pharmaceuticals, Ltd. (Raleigh, NC)
Application Number:	12/393,979
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,309,569
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,309,569

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes						TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes						TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.

International Family Members for US Patent 8,309,569

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009219240
Australia	2010292043
Brazil	112012005627
Brazil	PI0908026
Canada	2716578